Chief Executive Officer

Ms. Christy Ma is SCG’s Co-founder, CEO and Managing Director. Ms. Ma specializes in oncology and immunotherapy drug development. Before joining SCG, she served in various positions in Clinical Operations and Pharmacovigilance at Genentech, BioMarin and Five Prime Therapeutics Inc., with participation in the development of Talzenna® (talazoparib), Cabiralizumab in combination with Opdivo® (nivolumab), Herceptin® (trastuzumab) and Avastin® (bevacizumab). Christy received a B.S. degree in Chemical Biology from the University of California, Berkeley and her M.S. in Medical Product Development Management from San Jose State University. 

Christy Ma, MS

Ke Zhang, PhD

Chief Scientific Officer

Dr. Ke Zhang is SCG’s Chief Scientific Officer and a member of the Board of Directors. Before joining SCG, Dr. Zhang acted as the principal project leader at Janssen/Johnson & Johnson R&Dand led several innovative projects. He has received the EASL Young Researcher Award. Dr. Zhang earned his PhD in Molecular Medicine at Faculty of Medicine, Technical University of Munich and received his postdoc training at Institute of Medical Virology, German National Research Center for Environmental Health.

Wolfgang Uckert, PhD

Chief Innovation Officer

Dr. Wolfgang Uckert is SCG’s Chief Innovation Officer.  Dr. Uckert is one of the pioneering scientists in cell therapy and the inventor of a high affinity TCR screening technology platform.He spent nearly 40 years in the field of genetic and molecular cell biology research and was rated the top 0.5% expert of cell therapy by Expertscape.  
Dr. Uckert was a Former Director of the Institute for Cell, Molecular Biology and Gene Therapy, Center for Molecular Medicine, University of Berlin, Germany. 

Karin Wisskirchen, PhD

Head of Research, SCG Germany

Dr. Wisskirchen heads SCG’s early research efforts and is also a postdoctoral fellow at the Institute of Virology in Munich. She is a leading expert in the field of adoptive T cell therapy of chronic hepatitis B and HBV-induced hepatocellular carcinoma and has received numerous honors and awards, such as the "GASL price of the YAEL foundation" in 2020, the twice the "Young Investigator Award" of the International Society for Cellular Therapy.  Dr. Wisskirchen received her PhD in virology from Technical University of Munich and her diploma in Biology from the Philipps University of Marburg.

Carol Yuen, LLM

Chief Business Officer

Ms. Carol Yuen is SCG’s Chief Business Officer of SCG. She has more than 25 years of financial experience, completed over US$35 billion worth of transactions. Before joining SCG, Ms. Yuen held senior positions with Goldman Sachs, Standard Chartered, Citigroup, and HSBC Group. She also serve as the Board Member of McGill University’s Asia Advisory Group and Co-Chair of the Financial Services Committee at The Canadian Chamber of Commerce in Hong Kong.